Literature DB >> 3680528

Structural relationship of human apolipoprotein B48 to apolipoprotein B100.

T L Innerarity1, S G Young, K S Poksay, R W Mahley, R S Smith, R W Milne, Y L Marcel, K H Weisgraber.   

Abstract

Although the complete amino acid sequence of human apolipoprotein (apo) B100 is known (4536 amino acids), the structure of apo B48 has not been defined. The objective of our study was to define the structure of apo B48 and its relationship to apo B100. Antibodies were produced against 22 synthetic peptides corresponding to sequences in human apo B100. The levels of immunoreactivity of the antipeptides to apo B100 and apo B48 were used to define the structural relationship between these two species of apo B. Six antibodies from sequences in the amino-terminal half of apo B100, including antipeptide 2110-2129, bound to both apo B100 and apo B48. 15 other apo B-specific antipeptides from sequences carboxyl-terminal to residue 2152 bound to apo B100, but not to apo B48. Immunoblots of cyanogen bromide digests of apo B100 and apo B48 with antipeptides 2068-2091 and 2110-2129 detected a 16-KD fragment (residues 2016-2151) in the apo B100 digest and a fragment of identical size in the apo B48 digest. Because apo B48 appears to contain the apo B100 cyanogen bromide fragment 2016-2151 and because an antiserum specific for the peptide 2152-2168 does not bind to apo B48, we conclude that apo B48 represents the amino-terminal 47% of apo B100 and that the carboxyl terminus of apo B48 is in the vicinity of residue 2151 of apo B100.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680528      PMCID: PMC442455          DOI: 10.1172/JCI113273

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  High-resolution preparative SDS-polyacrylamide gel electrophoresis: fluorescent visualization and electrophoretic elution-concentration of protein bands.

Authors:  R E Stephens
Journal:  Anal Biochem       Date:  1975-05-12       Impact factor: 3.365

2.  Antibodies that react with predetermined sites on proteins.

Authors:  J G Sutcliffe; T M Shinnick; N Green; R A Lerner
Journal:  Science       Date:  1983-02-11       Impact factor: 47.728

3.  Characterization of monoclonal antibodies against human low density lipoprotein.

Authors:  R W Milne; R Theolis; R B Verdery; Y L Marcel
Journal:  Arteriosclerosis       Date:  1983 Jan-Feb

4.  Mapping of antigenic determinants of human apolipoprotein B using monoclonal antibodies against low density lipoproteins.

Authors:  Y L Marcel; M Hogue; R Theolis; R W Milne
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

5.  Antibodies against the chemically synthesized genome-linked protein of poliovirus react with native virus-specific proteins.

Authors:  M H Baron; D Baltimore
Journal:  Cell       Date:  1982-02       Impact factor: 41.582

Review 6.  Apolipoprotein B: structural and metabolic heterogeneity.

Authors:  J P Kane
Journal:  Annu Rev Physiol       Date:  1983       Impact factor: 19.318

7.  Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons.

Authors:  J P Kane; D A Hardman; H E Paulus
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

Review 8.  Hypolipidemia.

Authors:  M J Malloy; J P Kane
Journal:  Med Clin North Am       Date:  1982-03       Impact factor: 5.456

9.  A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine.

Authors:  L M Powell; S C Wallis; R J Pease; Y H Edwards; T J Knott; J Scott
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

10.  Cholesteryl ester accumulation in mouse peritoneal macrophages induced by beta-migrating very low density lipoproteins from patients with atypical dysbetalipoproteinemia.

Authors:  T P Bersot; T L Innerarity; R W Mahley; R J Havel
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

View more
  9 in total

1.  Is it time to break the fast?-a paradigm shift in clinical lipidology.

Authors:  Manuel Castro Cabezas; Benjamin Burggraaf; Boudewijn Klop
Journal:  Ann Transl Med       Date:  2016-11

2.  Human small-intestinal apolipoprotein B-48 oligosaccharide chains.

Authors:  W V Sasak; J S Lown; K A Colburn
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

3.  A truncated species of apolipoprotein B (B67) in a kindred with familial hypobetalipoproteinemia.

Authors:  F K Welty; S T Hubl; V R Pierotti; S G Young
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

4.  Determinants of ApoB, ApoA1, and the ApoB/ApoA1 ratio in healthy schoolgirls, prospectively studied from mean ages 10 to 19 years: the Cincinnati National Growth and Health Study.

Authors:  John A Morrison; Charles J Glueck; Stephen R Daniels; Paul S Horn; Ping Wang
Journal:  Metabolism       Date:  2012-04-16       Impact factor: 8.694

5.  Reading-frame restoration with an apolipoprotein B gene frameshift mutation.

Authors:  M F Linton; V Pierotti; S G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

6.  Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products.

Authors:  X Wang; R Bucala; R Milne
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

7.  Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse.

Authors:  Y Osono; L A Woollett; J Herz; J M Dietschy
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

Review 8.  Dyslipidemia in obesity: mechanisms and potential targets.

Authors:  Boudewijn Klop; Jan Willem F Elte; Manuel Castro Cabezas
Journal:  Nutrients       Date:  2013-04-12       Impact factor: 5.717

9.  Correlation Between the APOB rs1042034 SNP and Blood Lipid Characteristics of 2 Ethnic Groups in China.

Authors:  Fen-Han Zhang; Rui-Xing Yin; Li-Mei Yao; Rong-Qin Yan; Li Lu; Yuan Su
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.